The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment
Abstract
Purpose: To evaluate the emerging role of immunomodulatory antibodies in cancer treatment. Antibodies (ipilimumab and tremelimumab) targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), an inhibitory molecule on T cells, represent the vanguard of these new drugs. Design: We performed a systematic review of the clinical studies examining the clinical activity of anti–CTLA-4 antibodies. We also review the potential mechanisms and toxicities associated with these treatments. Results: Clinical activity with anti–CTLA-4 monoclonal antibodies (mAbs) has paved the way for additional T-cell immunomodulatory monoclonal antibody (mAb) approaches for the treatment of cancer to be investigated. Because anti–CTLA-4 mAbs target the immune system and not the tumor, they may provide significant potential advantages over traditional antitumor mAbs, chemotherapies, and immunotherapies (ie, vaccines and cytokines). Other antibodies, such as CD137 agonists, CD40 agonists, and PD-1 antagonists, are currently in various stages of preclinical and clinical development. Conclusion: Available clinical data suggest that anti–CTLA-4 mAbs are very different from traditional mAbs, chemotherapies, and immunotherapies in terms of patterns of response, duration of response, and adverse event profile. Ongoing clinical studies aim to establish the efficacy and safety of anti–CTLA-4 mAbs as monotherapy or in combination with other drugs for the treatment of metastatic melanoma and a variety of other cancer types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766 · cited 1×
“In animal models, CTLA-4 proved critical in the normal functioning immune system; CTLA-4 knockout mice developed uncontrolled lymphoproliferation with early lethalities.(29,30) Theoretically, blocking CTLA-4 using mAbs may sustain the activation and proliferation of tumorspecific T cells, therefore initiating the deve…”
BackgroundCD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., & Montero, A. J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,215
Demaria, S., Kawashima, N., Yang, A. M., Devitt, M. L., Babb, J. S., Allison, J. P., & Formenti, S. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.728.11.2 · Cited by 1,022
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
Linsley, P. S., Greene, J. L., Brady, W., Bajorath, J., Ledbetter, J. A., & Peach, R. (1994) · Immunity · doi:10.1016/s1074-7613(94)80021-9 · Cited by 980
Ghiringhelli, F., Ménard, C., Terme, M., Flament, C., Taieb, J., Chaput, N., Puig, P. E., Novault, S., Escudier, B., Vivier, E., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051511 · Cited by 949
Krummel, M. F., & Allison, J. P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.6.2533 · Cited by 932
Beck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5716 · Cited by 833
Hodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., MacRae, S., Nelson, M., Canning, C., Lowy, I., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712237105 · Cited by 650
Blank, C., Gajewski, T. F., & Mackensen, A. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0593-x · Cited by 637
Ribas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.109 · Cited by 591 · cited 1×
“Durable OR, SD, and prolonged survival have also been observed in patients treated with tremelimumab (Table 2).(63,65) This durability of response or SD is not observed in response to cytotoxic agents or cytokines for MM, and unlike SD that occurs in response to chemotherapy, anti–CTLA-4– mediated SD seems to allow pa…”
BackgroundAutoantibody Signatures in Prostate Cancer
Wang, X., Yu, J., Sreekumar, A., Varambally, S., Shen, R., Giacherio, D., Mehra, R., Montie, J. E., Pienta, K. J., Sanda, M. G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051931 · Cited by 582
Checkpoint Blockade in Cancer Immunotherapy
Korman, A. J., Peggs, K. S., & Allison, J. P. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90008-x · Cited by 570
Control of T‐cell activation by CD4+ CD25+ suppressor T cells
Shevach, E. M., McHugh, R. S., Piccirillo, C. A., & Thornton, A. M. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820104.x · Cited by 546
Maker, A. V., Phan, G. Q., Attia, P., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Haworth, L. R., Levy, C., et al. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.03.536 · Cited by 492
Zhang, W., Gordon, M., Schultheis, A. M., Yang, D. Y., Nagashima, F., Azuma, M., Chang, H.-M., Borucka, E., Lurje, G., Sherrod, A. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8021 · Cited by 482
Management and Preparedness for Infusion and Hypersensitivity Reactions
Lenz, H.-J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-5-601 · Cited by 479
Oppenheim, D. E., Roberts, S. J., Clarke, S. L., Filler, R., Lewis, J. M., Tigelaar, R. E., Girardi, M., & Hayday, A. C. (2005) · Nature Immunology · doi:10.1038/ni1239 · Cited by 454
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
Peggs, K. S., Quezada, S. A., Korman, A. J., & Allison, J. P. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.01.011 · Cited by 445
Sanderson, K., Scotland, R., Lee, P., Liu, D., Groshen, S., Snively, J., Sian, S., Nichol, G., Davis, T., Keler, T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.128 · Cited by 434
Valzasina, B., Guiducci, C., Dislich, H., Killeen, N., Weinberg, A. D., & Colombo, M. P. (2005) · Blood · doi:10.1182/blood-2004-07-2959 · Cited by 428
Hurwitz, A. A., Foster, B. A., Kwon, E. D., Truong, T. N., Choi, E. M., Greenberg, N. M., Burg, M. B., & Allison, J. P. (2000) · PubMed · Cited by 425
Small, E. J., Tchekmedyian, N. S., Rini, B. I., Fong, L., Lowy, I., & Allison, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2318 · Cited by 407
Self-citationManipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer
Kwon, E. D., Hurwitz, A. A., Foster, B. A., Madias, C., Feldhaus, A. L., Greenberg, N. M., Burg, M. B., & Allison, J. P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.8099 · Cited by 394
Hurwitz, A. A., Yu, T. F.-Y., Leach, D. R., & Allison, J. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.10067 · Cited by 378
Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?
Muranski, P., Boni, A., Wrzesinski, C., Citrin, D. E., Rosenberg, S. A., Childs, R., & Restifo, N. P. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0666 · Cited by 358
Blansfield, J. A., Beck, K. E., Tran, K., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Topalian, S. L., Haworth, L. R., Levy, C., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000178913.41256.06 · Cited by 355
Maker, A. V., Attia, P., & Rosenberg, S. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.11.7746 · Cited by 343
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction
Contardi, E., Palmisano, G. L., Tazzari, P. L., Martelli, A. M., Falà, F., Fabbi, M., Kato, T., Lucarelli, E., Donati, D., Polito, L., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21155 · Cited by 324
Weber, J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-7-864 · Cited by 286
Shrikant, P., Khoruts, A., & Mescher, M. F. (1999) · Immunity · doi:10.1016/s1074-7613(00)80123-5 · Cited by 283
Hatjiharissi, E., Xu, L., Santos, D. D., Hunter, Z. R., Ciccarelli, B. T., Verselis, S., Modica, M., Cao, Y., Manning, R. J., Leleu, X., et al. (2007) · Blood · doi:10.1182/blood-2007-01-070656 · Cited by 282
Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma
Maker, A. V., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Hughes, M., Yellin, M. J., Haworth, L. R., Levy, C., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000208259.73167.58 · Cited by 265
Hudson, M. E., Pozdnyakova, I., Haines, K., Mor, G., & Snyder, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708572104 · Cited by 261
Kavanagh, B., O'Brien, S., Lee, D., Hou, Y., Weinberg, V., Rini, B., Allison, J. P., Small, E. J., & Fong, L. (2008) · Blood · doi:10.1182/blood-2007-11-125435 · Cited by 256
Self-citationStowell, S. R., Qian, Y., Karmakar, S., Koyama, N. S., Dias-Baruffi, M., Leffler, H., McEver, R. P., & Cummings, R. D. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.3091 · Cited by 255
The Role of CTLA‐4 in the Regulation and Initiation of T‐Cell Responses
Chambers, C. A., Krummel, M. E., Boitel, B., Hurwitz, A., Sullivan, T. J., Fournier, S., Cassell, D., Brunner, M., & Allison, J. P. (1996) · Immunological Reviews · doi:10.1111/j.1600-065x.1996.tb00919.x · Cited by 211
Sznol, M., Hodi, F. S., Margolin, K., McDermott, D. F., Ernstoff, M. S., Kirkwood, J. M., Wojtaszek, C., Feltquate, D., & Logan, T. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3007 · Cited by 204
de Vries, I. J. M., Bernsen, M. R., Lesterhuis, W. J., Scharenborg, N. M., Strijk, S. P., Gerritsen, M.-J. P., Ruiter, D. J., Figdor, C. G., Punt, C. J. A., & Adema, G. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.478 · Cited by 188
Dávila, E., Kennedy, R. B., & Celis, E. (2003) · PubMed · Cited by 182
Jinushi, M., Hodi, F. S., & Dranoff, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603503103 · Cited by 168
Sotomayor, E. M., Borrello, I., Tubb, E. E., Allison, J. P., & Levitsky, H. I. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11476 · Cited by 157
Ribas, A., Hauschild, A., Kefford, R. F., Punt, C. J. A., Haanen, J. B. A. G., Mármol, M., Garbe, C., Gómez-Navarro, J., Pavlov, D., & Marshall, M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.lba9011 · Cited by 155
Haanen, J. B. A. G., Baars, A., Gomez, R., Weder, P., Smits, M., de Gruijl, T. D., Blomberg, B. M. E. V., Bloemena, E., Scheper, R. J., van Ham, S. M., et al. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0018-5 · Cited by 152
Krummel, M. F., Sullivan, T. J., & Allison, J. P. (1996) · International Immunology · doi:10.1093/intimm/8.4.519 · Cited by 150
MOKYR, M. B., Kalinichenko, T. V., Gorelik, L., & Bluestone, J. A. (1998) · PubMed · Cited by 147
Myeloid-Derived Suppressor Cells
Nagaraj, S., & Gabrilovich, D. I. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-72005-0_22 · Cited by 137
Tumor immune escape mediated by indoleamine 2,3-dioxygenase
Ζαμανάκου, Μ., Germenis, A. E., & Karanikas, V. (2007) · Immunology Letters · doi:10.1016/j.imlet.2007.06.001 · Cited by 132
Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
Korman, A. J., Yellin, M. J., & Keler, T. (2005) · PubMed · Cited by 85
Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative
Peggs, K. S., Segal, N. H., & Allison, J. P. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.023 · Cited by 79
Hamid, O., Chin, K., Li, J., Neyns, B., Linette, G. P., Négrier, S., Lutzky, J., Hoos, A., Wolchock, J. D., & Lebbé, C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.9025 · Cited by 48
Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma
Hamid, O., Urba, W. J., Yellin, M. J., Nichol, G., Weber, J. S., Hersh, E. M., Tchekmedyian, S., Hodi, F. S., Weber, R. W., & O'Day, S. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.8525 · Cited by 41
Ribas, A., Antonia, S. J., Sosman, J. A., Kirkwood, J. M., Redman, B. G., Gajewski, T. F., Pavlov, D., Bulanhagui, C. A., Navarro, J. G., & Camacho, L. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3000 · Cited by 38
Weber, J. S., Hersh, E. M., Yellin, M. J., Nichol, G., Urba, W. J., Powderly, J. D., & O'Day, S. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.8523 · Cited by 37
O'Day, S. J., Ibrahim, R. A., DePril, V., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.9021 · Cited by 35
Hodi, F. S., Hoos, A., Ibrahim, R., Chin, K. M., Pehamberger, H., Harmankaya, K., O'Day, S., Hamid, O., Humphrey, R. W., & Wolchok, J. D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3008 · Cited by 34
Weber, J. S., Berman, D. M., Siegel, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.9010 · Cited by 31
Ribas, A., Bozon, V. A., Lopez‐Berestein, G., Pavlov, D., Reuben, J. M., Parker, C., Seja, E., Glaspy, J. A., Gómez-Navarro, J., & Camacho, L. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.7524 · Cited by 31
Hersh, E. M., Weber, J. S., Powderly, J. D., Khan, K. D., Pavlick, A. C., Samlowski, W. E., O'Day, S. J., Nichol, G., Yellin, M. J., & Cramner, L. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.9022 · Cited by 30
Gómez-Navarro, J., Antonia, S. J., Sosman, J. A., Kirkwood, J. M., Redman, B. G., Gajewski, T. F., Pavlov, D., Bulanhagui, C. A., Ribas, A., & Camacho, L. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.8524 · Cited by 19
Gerritsen, W. R., van den Eertwegh, A. J. M., de Gruijl, T. D., Giaccone, G., Scheper, R. J., Sacks, N., Harding, T. C., Lowy, I., Stankevich, E., & Hege, K. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.5120 · Cited by 15
Natural history of diarrhea associated with the anti-CTLA4 monoclonal antibody CP-675,206
Antonia, S., Sosman, J. A., Kirkwood, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3038 · Cited by 9
Tumor size, age and stage in patient detected breast cancer
Kaplan, H. G., Malmgren, J., & Atwood, M. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.716 · Cited by 8
Efficacy of anti-CTLA-4 antibody in the SA1N tumor model when combined with dexamethasone
Chen, B., Phillips, J., Greenbaum, M., Klitzing, D., Cardarelli, P. M., & Korman, A. J. (2007) · Cancer Research · Cited by 5
Regulation of fucosyltransferase-VII expression in peripheral lymph node high endothelial venules
(1998) · doi:10.1002/(sici)1521-4141(199810)28:10
Cited by
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Dewan, M. Z., Galloway, A. E., Kawashima, N., Dewyngaert, J. K., Babb, J. S., Formenti, S. C., & Demaria, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0265 · Cited by 1,678
Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70189-5 · Cited by 1,511
Metadata
- Authors
- Fong, L., & Small, E. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-11-10
- Volume
- 26
- Issue
- 32
- Pages
- 5275-5283
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2148586726
- Cited by
- 323
- References
- 75
- FWCI
- 13.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.